Clinical trial

Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

NCT04338022

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2020-06-12

PhasePHASE3

Study timeline

Study start (actual)2020-06-12Date precision: day

Registry last updated2025-06-12

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Multiple Sclerosisunresolved

Interventions

TeriflunomideDRUG · verified · RxNorm: teriflunomide

EvobrutinibDRUG

Sponsors & collaborators

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germanylead sponsor

EMD Serono Research & Development Institute, Inc.collaborator

Mapped research locations

SeoulSouth Korea6 SofiaBulgaria6 KharkivUkraine6 BudapestHungary5 MadridSpain3 PragueCzechia3 Buenos AiresArgentina3 BelgradeSerbia3 St LouisMissouri, United States2 NashvilleTennessee, United States2 BarcelonaSpain2 PhoenixArizona, United States2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04338022 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.